(Q35162317)

6 August 2017

1 reference

title

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence (English)

1 reference

6 August 2017

0 references

2

Robert J Heine

1 reference

6 August 2017

1

Michaela Diamant

1 reference

6 August 2017

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

63

1 reference

6 August 2017

13

1 reference

6 August 2017

1373-1405

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363130-00004

6 August 2017

0 references

1 reference

12 December 2020

Thiazolidinediones: a new class of antidiabetic drugs

1 reference

12 December 2020

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

12 December 2020

Insulin resistance--mechanisms, syndromes, and implications

1 reference

12 December 2020

Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy

1 reference

12 December 2020

Peroxisome proliferator-activated receptors: nuclear control of metabolism

1 reference

12 December 2020

Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes

1 reference

12 December 2020

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

1 reference

12 December 2020

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Effect of pioglitazone on vascular reactivity in vivo and in vitro

1 reference

12 December 2020

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

1 reference

12 December 2020

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

12 December 2020

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

1 reference

12 December 2020

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

12 December 2020

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

12 December 2020

A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones

1 reference

12 December 2020

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

1 reference

12 December 2020

Resistin, central obesity, and type 2 diabetes.

1 reference

12 December 2020

Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma

1 reference

12 December 2020

Differentiating members of the thiazolidinedione class: a focus on safety

1 reference

12 December 2020

Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats

1 reference

12 December 2020

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

12 December 2020

Troglitazone-induced heart and adipose tissue cell proliferation in mice

1 reference

12 December 2020

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

12 December 2020

Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans

1 reference

12 December 2020

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

12 December 2020

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

12 December 2020

Hepatocellular injury in a patient receiving rosiglitazone. A case report

1 reference

12 December 2020

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

12 December 2020

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

1 reference

12 December 2020

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

1 reference

12 December 2020

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats

1 reference

12 December 2020

The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients

1 reference

12 December 2020

PPARgamma, the ultimate thrifty gene

1 reference

12 December 2020

Roles of PPARs in health and disease.

1 reference

12 December 2020

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy

1 reference

12 December 2020

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer

1 reference

12 December 2020

Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice

1 reference

12 December 2020

The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial

1 reference

12 December 2020

Troglitazone selectively inhibits glyoxalase I gene expression

1 reference

12 December 2020

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

1 reference

12 December 2020

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

1 reference

12 December 2020

Glibenclamide-associated hypoglycaemia: a report on 57 cases

1 reference

12 December 2020

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

1 reference

12 December 2020

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Pathogenesis of non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

1 reference

12 December 2020

Lessons from the glitazones: a story of drug development

1 reference

12 December 2020

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

12 December 2020

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life

1 reference

12 December 2020

Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.

1 reference

12 December 2020

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

1 reference

12 December 2020

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

12 December 2020

Recent advances in our understanding of insulin action and insulin resistance

1 reference

12 December 2020

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

1 reference

12 December 2020

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

12 December 2020

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

1 reference

12 December 2020

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

1 reference

12 December 2020

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

1 reference

12 December 2020

Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease

1 reference

12 December 2020

Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats

1 reference

12 December 2020

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

1 reference

12 December 2020

Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus.

1 reference

12 December 2020

Insulin action and secretion in endurance-trained and untrained humans

1 reference

12 December 2020

Response of experimental retinal neovascularization to thiazolidinediones

1 reference

12 December 2020

Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose

1 reference

12 December 2020

Pioglitazone: mechanism of action.

1 reference

12 December 2020

Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men.

1 reference

12 December 2020

Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects.

1 reference

12 December 2020

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

1 reference

12 December 2020

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

1 reference

12 December 2020

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

12 December 2020

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome

1 reference

12 December 2020

Pathophysiology and pharmacological treatment of insulin resistance

1 reference

12 December 2020

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

1 reference

12 December 2020

Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

1 reference

12 December 2020

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect

1 reference

12 December 2020

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

1 reference

12 December 2020

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

1 reference

12 December 2020

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

12 December 2020

Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus.

1 reference

12 December 2020

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes

1 reference

12 December 2020

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

1 reference

12 December 2020

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

12 December 2020

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

1 reference

12 December 2020

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

1 reference

12 December 2020

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

1 reference

12 December 2020

Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations

1 reference

12 December 2020

In vitro studies on the action of CS-045, a new antidiabetic agent

1 reference

12 December 2020

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

1 reference

12 December 2020

1 reference

12 December 2020

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

12 December 2020

The hormone resistin links obesity to diabetes

1 reference

12 December 2020

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

12 December 2020

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

12 December 2020

Thiazolidinediones: an update.

1 reference

12 December 2020

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

12 December 2020

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

12 December 2020

Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling

1 reference

12 December 2020

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

1 reference

12 December 2020

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

12 December 2020

Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients

1 reference

12 December 2020

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

1 reference

12 December 2020

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

12 December 2020

1 reference

12 December 2020

Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study.

1 reference

12 December 2020

Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease

1 reference

12 December 2020

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

1 reference

12 December 2020

Hepatocellular injury in a patient receiving pioglitazone.

1 reference

12 December 2020

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

1 reference

12 December 2020

Life without white fat: a transgenic mouse

1 reference

12 December 2020

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

1 reference

12 December 2020

Hepatic failure in a patient taking rosiglitazone

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo

1 reference

12 December 2020

BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones

1 reference

12 December 2020

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

12 December 2020

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

12 December 2020

Diseases of liporegulation: new perspective on obesity and related disorders

1 reference

12 December 2020

Troglitazone and related compounds: therapeutic potential beyond diabetes

1 reference

12 December 2020

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

12 December 2020

Nonhypoglycemic effects of thiazolidinediones

1 reference

12 December 2020

Leptin-replacement therapy for lipodystrophy.

1 reference

12 December 2020

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

1 reference

12 December 2020

Thiazolidinediones and liver toxicity

1 reference

12 December 2020

Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.

1 reference

12 December 2020

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides

1 reference

12 December 2020

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

1 reference

12 December 2020

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

12 December 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

12 December 2020

Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.

1 reference

12 December 2020

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

12 December 2020

1 reference

12 December 2020

Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes

1 reference

12 December 2020

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

12 December 2020

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

1 reference

12 December 2020

Liver failure in a patient treated with long-term rosiglitazone therapy

1 reference

12 December 2020

The pleiotropic functions of peroxisome proliferator-activated receptor gamma

1 reference

12 December 2020

Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes

1 reference

12 December 2020

Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects

1 reference

12 December 2020

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

12 December 2020

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

1 reference

12 December 2020

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

12 December 2020

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

12 December 2020

The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease.

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis

1 reference

12 December 2020

The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

1 reference

12 December 2020

The perils of portliness: causes and consequences of visceral adiposity

1 reference

12 December 2020

Troglitazone action is independent of adipose tissue

1 reference

12 December 2020

PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success

1 reference

12 December 2020

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

1 reference

12 December 2020

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

12 December 2020

Lipotoxic heart disease in obese rats: implications for human obesity

1 reference

12 December 2020

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats

1 reference

12 December 2020

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

1 reference

12 December 2020

Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review

1 reference

12 December 2020

Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients

1 reference

12 December 2020

Peroxisome proliferator-activated receptors in inflammation control

1 reference

12 December 2020

Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.

1 reference

12 December 2020

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

1 reference

12 December 2020

10.2165/00003495-200363130-00004

Identifiers

DOI

1 reference

PubMed ID

12825962

Dimensions Publication ID

6 August 2017

0 references

1 reference

PubMed ID

12825962